Search Within

Gregory J Riely

Formats
  1. Journal Article (295)
  2. Meeting Abstract (265)
  3. Book Section (16)
  4. Guidelines (15)
  5. Conference Paper (4)
  6. Review (4)
  7. Editorial (3)
  8. Book Whole (1)
  9. Correspondence (1)
  10. Research Letter (1)
Groups
  1. Department of Medicine (605)
  2. Solid Tumor Oncology Division (605)
  3. Thoracic Oncology (605)
  4. Department of Pathology and Laboratory Medicine (262)
  5. GSK Faculty (248)
  6. Human Oncology and Pathogenesis Program (223)

More Groups

People
  1. Mark Kris (222)
  2. Marc Ladanyi (188)
  3. Helena Yu (108)
  4. Maria Arcila (85)
  5. Vincent Miller (79)
  6. Charles Rudin (76)

More People

Years
  1. 2025 (9)
  2. 2024 (25)
  3. 2023 (45)
  4. 2022 (39)
  5. 2021 (41)
  6. 2020 (29)

More Years

Publications
  1. Journal of Clinical Oncology (157)
  2. Journal of Thoracic Oncology (113)
  3. Clinical Cancer Research (46)
  4. Annals of Oncology (32)
  5. Journal of the National Comprehensive Cancer Network (26)
  6. Cancer Research (14)

More Publications

Publishers
  1. American Society of Clinical Oncology (175)
  2. Elsevier Inc. (137)
  3. American Association for Cancer Research (77)
  4. Oxford University Press (39)
  5. Harborside Press (26)
  6. Elsevier Science, Inc. (23)

More Publishers

Results (605)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Use of an Internet-based protocol to collect clinical information and blood from patients with lung cancer who never smoked cigarettes
    Meeting Abstract

    Girard, N.; Klein, R.; Riely, G. J.; Reddy, R.; Kris, M. G.; Pao, W.
    Journal of Clinical Oncology (2009)

    Fulltext@MSK | Save
  • Rebiopsy of patients (pts) with acquired resistance to epidermal growth factor tyrosine kinase inhibitors (EGFR-TKIs) in non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Arcila, M. E.; Riely, G. J.; Zakowski, M. F.; Kris, M. G.; Ladanyi, M.; Pao, W.; Miller, V. A.
    Journal of Clinical Oncology (2009)

    Fulltext@MSK | Save
  • Reflex testing of lung adenocarcinomas for EGFR and KRAS mutations: The initial Memorial Sloan-Kettering Cancer Center (MSKCC) experience
    Meeting Abstract

    Zakowski, M. F.; Ladanyi, M.; Rekhtman, N.; Park, B.; Finley, D.; Azzoli, C.; Kris, M. G.; Rusch, V.; Miller, V.; Riely, G.
    Journal of Thoracic Oncology (2009)

    Fulltext@MSK | Save
  • Comparison of CISH and FISH for detection of EGFR copy number in lung adenocarcinomas and correlation with EGFR and KRAS mutation status and EGFR immunohistochemistry reactivity
    Meeting Abstract

    Varella, G. M.; Ladanyi, M.; Kris, M. G.; Rekhtman, N.; Hirsch, F.; Miller, V.; Riely, G.; Pao, W.; Zakowski, M. F.
    Journal of Thoracic Oncology (2009)

    Fulltext@MSK | Save
  • The new IASLC/ATS/ERS international multidisciplinary lung adenocarcinoma classification
    Meeting Abstract

    Travis, W. D.; Brambilla, E.; Noguchi, M.; Geisinger, K.; Beer, D.; Powell, C. A.; Johnson, B.; Riely, G. J.; Rusch, V.; Asamura, H.; more...
    Journal of Thoracic Oncology (2009)

    Fulltext@MSK | Save
  • Recent clinical experience with thymic neuroendocrine tumors
    Meeting Abstract

    Towe, C.; Huang, J.; Travis, W.; Riely, G. J.; Dycoco, J.; Rizk, N.; Park, B.; Bains, M.; Flores, R.; Downey, R.; more...
    Journal of Thoracic Oncology (2009)

    Fulltext@MSK | Save
  • Phase 1 trial of cetuximab and erlotinib in patients with lung adenocarcinoma and acquired resistance to erlotinib
    Meeting Abstract

    Riely, G. J.; Janjigian, Y. Y.; Pereira, L. K.; Azzoli, C. G.; Pietanza, M. C.; Krug, L. M.; Rizvi, N. A.; Kris, M. G.; Ginsberg, M. S.; Pao, W.; more...
    Journal of Thoracic Oncology (2009)

    Fulltext@MSK | Save
  • Analysis of EGFR and KRAS mutations in high-grade neuroendocrine carcinomas of the lung
    Meeting Abstract

    Rekhtman, N.; He, M.; Lau, C.; Nafa, K.; Riely, G. J.; Zakowski, M. F.; Ladanyi, M.
    Modern Pathology (2009)

    Fulltext@MSK | Save
  • Rebiopsy of patients with "acquired resistance" to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Miller, V. A.; Riely, G. J.; Arcila, M. E.; Oxnard, G.; Zakowski, M. F.; Kris, M. G.; Pao, W.; Ladanyi, M.
    Journal of Thoracic Oncology (2009)

    Fulltext@MSK | Save
  • Phase II trial of dasatinib for patients demonstrating acquired resistance to treatment with the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) erlotinib (E) or gefitinib (G)
    Meeting Abstract

    Johnson, M. L.; Riely, G. J.; Rizvi, N. A.; Azzoli, C. G.; Kris, M. G.; Ginsberg, M. S.; Pao, W.; Miller, V. A.
    Journal of Thoracic Oncology (2009)

    Fulltext@MSK | Save